KORU Medical Systems (NASDAQ:KRMD – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Sunday, Wall Street Zen reports.
KRMD has been the topic of a number of other reports. Zacks Research lowered shares of KORU Medical Systems from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 30th. Piper Sandler reiterated a “neutral” rating and issued a $4.50 price objective (down from $5.00) on shares of KORU Medical Systems in a report on Wednesday, November 11th. Weiss Ratings downgraded shares of KORU Medical Systems from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, September 29th. Finally, Craig Hallum reissued a “buy” rating and issued a $6.00 target price on shares of KORU Medical Systems in a research note on Thursday, August 6th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $6.50.
Check Out Our Latest Report on KORU Medical Systems
KORU Medical Systems Stock Performance
Shares of KRMD stock opened at $3.69 on Friday. KORU Medical Systems has a fifty-two week low of $2.86 and a fifty-two week high of $6.61. The stock’s fifty day moving average is $3.16 and its two-hundred day moving average is $3.91.
KORU Medical Systems (NASDAQ:KRMD – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.04. The business had revenue of $11.57 million during the quarter, compared to analyst estimates of $11.33 million. KORU Medical Systems had a negative net margin of 1.78% and a negative return on equity of 4.62%. On average, equities analysts predict that KORU Medical Systems will post -0.02 earnings per share for the current year.
Insider Transactions at KORU Medical Systems
In related news, insider Adam Kalbermatten bought 32,000 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was bought at an average cost of $3.16 per share, for a total transaction of $101,120.00. Following the acquisition, the insider directly owned 394,017 shares in the company, valued at $1,245,093.72. This represents a 8.84% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 18.50% of the stock is currently owned by insiders.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new position in shares of KORU Medical Systems during the 2nd quarter valued at about $11,039,000. Meros Investment Management LP acquired a new stake in KORU Medical Systems during the second quarter worth about $3,190,589. Royal Bank of Canada increased its position in KORU Medical Systems by 77.3% during the first quarter. Royal Bank of Canada now owns 235,804 shares of the company’s stock worth $1,019,000 after purchasing an additional 102,800 shares during the last quarter. White Pine Capital LLC acquired a new stake in KORU Medical Systems during the third quarter worth about $840,000. Finally, Marshall Wace LLP raised its stake in KORU Medical Systems by 1,039.3% during the third quarter. Marshall Wace LLP now owns 244,902 shares of the company’s stock worth $718,000 after purchasing an additional 223,406 shares during the period. Hedge funds and other institutional investors own 58.60% of the company’s stock.
KORU Medical Systems Company Profile
KORU Medical Systems develops, manufactures and markets medical devices used to deliver medications under the skin, or subcutaneously. Its products are designed for patients receiving therapies outside traditional infusion settings, including at home. The company’s product line includes the Freedom60 and FreedomEDGE ambulatory infusion pumps, Precision Flow Rate Tubing and HIgH-Flo subcutaneous needle sets. These products are used with subcutaneous immunoglobulin and other specialty therapies. Founded in 1980 as Repro Med Systems, the company adopted the name KORU Medical Systems in 2020.
Further Reading
- Five stocks we like better than KORU Medical Systems
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
